Jul 21, 2016 - Gilead Sciences (GILD), which is set to report second-quarter 2016 results on Jul 25, delivered a negative earnings surprise of 1.65% last quarter.
Jul 21, 2016 - Eli Lilly (LLY) looks poised to beat analyst estimates this earnings season, with a favorable Zacks Rank and an ESP in positive territory.
Jul 21, 2016 - The combination of Lilly's Zacks Rank #3 and +1.18% ESP makes us very confident in looking for a positive earnings beat on Jul 26.
Jul 15, 2016 - Will Tecfidera scrips and sales recover enough to boost Biogen's (BIIB) performance in the second quarter?
Jul 15, 2016 - J&J (JNJ) has a pretty good track record and could beat estimates in the second quarter given the Zacks Rank #2 and +1.80% ESP.
Jul 14, 2016 - Eli Lilly (LLY) inked a clinical trial collaboration with Boehringer for the evaluation of abemaciclib-BI 836845 combination for metastatic breast cancer.
Apr 26, 2016 - Eli Lilly & Co. (NYSE:LLY)Q1 2016 Earnings CallApril 26, 2016 9:00 am ETExecutivesJohn C. Lechleiter - Chairman, President & Chief Executive OfficerPhilip Johnson - Vice President, Investor Relations,
Apr 26, 2016 - Earnings Conference Call Start time: April 26, 2016 at 09:00 AM ET.The audio will stream live while the call is active and can be replayed upon its completion.
Sep 22, 2015 - Shire's (SHPG) once-daily, non-stimulant Intuniv received European approval for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Sep 18, 2015 - TG Therapeutics (TGTX) reached an agreement with the FDA related to a Special Protocol Assessment of a phase III study design for TG-1101 for chronic lymphocytic leukemia.